VivoSeq
Infectious Disease

Helicobacter Pylori

0

Pipeline Programs

13

Active Trials

2

Companies Involved

Helicobacter Pylori is an early-stage landscape with 0 programs across 2 companies. The most active players are RedHill Biopharma Limited, Takeda.

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

4/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

90

clinical trials

Completed49 · 54%
Unknown status24 · 27%
Recruiting5 · 6%
Not yet recruiting4 · 4%
Active, not recruiting3 · 3%
Withdrawn3 · 3%
Other2 · 2%

Trial Activity

90 trials

Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)